1 / 31

Approach to Acute Renal Failure

Approach to Acute Renal Failure. Dr. Mercedeh Kiaii St. Pauls Hospital. Acute Renal Failure. Definition: Abrupt decrease in GFR sufficient to result in azotemia Urine output can be low, normal or high Anuric: < 100 ml/day Oliguric: < 400 ml/day Non-oliguric: > 400 ml/day.

trudy
Télécharger la présentation

Approach to Acute Renal Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Approach to Acute Renal Failure Dr. Mercedeh Kiaii St. Pauls Hospital

  2. Acute Renal Failure • Definition: Abrupt decrease in GFR sufficient to result in azotemia • Urine output can be low, normal or high • Anuric: < 100 ml/day • Oliguric: < 400 ml/day • Non-oliguric: > 400 ml/day

  3. ARF: Approach • Assess severity and need for acute dialysis • Fluid overload •  k,  HC03 • Uremic encephalopathy • Uremic pericarditis

  4. ARF: Approach • R/O chronic or acute on chronic RF • History: • Fatigue, anorexia, nocturia, pruritis, restless legs • Lab: • Anemia,  PO4,  Ca,  iPTH • U/S: • Small (< 8 cm)  Chronic • Normal ( ~9-12)  Acute or Chronic

  5. ARF: Approach • Cause of ARF: • Pre-renal • Renal • Post-renal

  6. Pre-renal ARF • Decrease in effective circulating volume (ECFV): • True decrease in intravascular volume • Diarrhea, diuretic, hemorrhage etc • Relative decrease in volume • 3rd spacing, poor cardiac output state

  7. Pre-renal ARF:Approach • History • P/E • Lab: • Urine Na < 30 • FeNa < 1% (Una X Pcr) / (Pna X Ucr) •  BUN out of proportion to creat • R/O other causes of increase in serum BUN

  8. ARF: Post-renal • History: • Change in urine output • Pain • Phx of stones, or BPH, prostate or cervical ca • P/E: • Bladder distension • Prostate enlargement

  9. ARF: Post-renal • U/S: Hydronephrosis, hydroureter unless: • Too early • Volume depletion • Retroperitoneal fibrosis • Diuresis renography or urography to rule out nonobstructive urinary tract dilatation

  10. ARF: Post-renalEtiology • Intrarenal: • Stones • Papillary necrosis • Tumor, clot • Intratubular: uric acid, calcium oxalate, acyclovir, methotrexate • Extrarenal

  11. ARF: Intrinsic renal • Vascular • Main renal artery and intra-renal arteries & arterioles • Glomerular • Interstitial • Tubular

  12. ARF: Intrinsic RenalVascular • Urinalysis: Bland • DDx: • Atheroembolic disease, Cholesterol emboli • TTP, PAN • Scleroderma, malignant hypertension • Drugs: • Cyclosporine, tacrolimus • NSAIDS • Cocaine

  13. ARF: Intrinsic RenalGlomerular • Nephritic  RBC +/- RBC casts, protein on urinalysis • RPGN • Nephrotic  < 10 RBC (if present), nephrotic range proteinuria ( > 3 g/d) • Mixed (Nephritic / Nephrotic): • MPGN

  14. ARF: GlomerularNephritic ( RPGN) RPGN Pauci-immune (IF negative) Immune complex Disease Granular Ig deposition Linear Ig deposition -Wegeners -Microscopic polyarteritis -Churgstraus -Polychondritis -SLE -PIGN -SBE -Anti-GBM -Goodpasteurs

  15. ARF: GlomerularNephrotic • Primary: • Membranous, FSGS, MCD • Secondary: • DM, MM, Amyloid • Usually superimposed acute insult in setting of nephrosis  ARF • ATN in MCD • RVT in Membranous • Papillary necrosis in DM • Intratubular obstruction in MM

  16. ARF: Interstitial Nephritis • 30% have systemic manifestations • Urinalysis: WBC +/- WBC casts, eosinophils • Etiology: • Drugs: • Abx: penicillins, cephalosporins, sulfonamides, and rifampin • NSAIDS • Diuretics (thiazides, furosemide)

  17. ARF: Interstitial Nephritis • Etiology: • Infections: • Pyelonephritis • Systemic infection Immunologic disorders • Sjogrens • Other • Sarcoidosis • Idiopathic

  18. ARF: Acute tubular necrosis • Urinalysis: Brown granular casts +/- small amount of protein • Ischemic • Toxic: • Endogenous: • Myoglobin, Hemoglobin, uric acid • Exogenous: • AG, Amphotericin, contrast dye, acyclovir, indinovir

  19. ARFCase presentation • 57 y/o male • Phx of CAD with CAGB, gout, borderline hypertension, gastritis • Presented to ER with hx of melena stool for 2 days • No active bleeding in ER, stable • Hgb 60, Creat 295

  20. ARFCase Presentation: Approach • Severity of renal insufficiency? • Estimated CrCl: • (140-57)(75 kg) / 295 X 1.2 = 25 ml/min • Determine need for hemodialysis?

  21. ARFCase Presentation: Approach • Acute, chronic or acute on chronic? • Hgb not helpful, Po4 & Ca normal • U/S: Normal sized kidneys, symmetric • Etiology of ARF: • Prerenal, renal or postrenal? • Intravascular volume depletion 2ndary to blood loss • EF not known ( hx of cardiac disease) • Recent NSAID use for gout

  22. ARFCase Presentation: Approach • Investigations: • Una < 5 • U/S: no hydronephrosis • Urinalysis not available • Diagnosis: • ARF secondary to pre-renal state secondary to blood loss and NSAID use

  23. ARFCase Presentation: Approach • Pt d/c’d home and adviced to increase po salt and fluid intake, and avoid NSAIDS, booked for outpt scope, and started on Iron therapy • F/U: • Hgb 68, scope shows H. pylori • Creat 255

  24. ARFCase Presentation: Approach • Possible underlying chronic renal disease? • Risk factors: • Hypertension • Gout • Renovascular disease • U/S normal size kidneys in CRF in: • DM, Amyloid, PCKD

  25. ARFCase Presentation: Approach • DDx of ARF: • Vascular: ? TTP, ? PAN • Tubular: • Ischemic ATN from volume depletion & hypoperfusion, and intrarenal v/c from NSAIDS • Toxic ATN secondary to uric acid crystals • Interstitial nephritis secondary to NSAIDS • Glomerular

  26. ARFCase Presentation: Approach • Urinalysis: • No blood, no WBC, > 5.0 g/l protein • 24 hour urine: 6 g/day protein

  27. ARFCase Presentation: Approach • DDx (Nephrotic): • Minimal change disease 2ndary to NSAIDS • Membranous 2ndary to NSAIDS • no known hx of Hep B • FSGS • Systemic causes • ? Multiple myeloma, ? amyloid

  28. ARFCase Presentation: Approach • UPEP: Suspicious for monoclonal protein, immunofixation pending • SPEP: Normal

  29. ARF:Treatment Strategies • Treat obvious reversible factors: • Pre-renal state, obstruction • Remove possible nephrotoxins • Treat possible RPGN early • Dopamine and mannitol not effective • ANP in oliguric ATN • Urine alkalinization

  30. ARF:Treatment Strategies • Avoid other nephrotoxins • Avoid ischemic episodes and volume depletion • Loss of autoregulation • Loss of tubular function

  31. ARF:Treatment Strategies • Dialysis therapy: • Daily vs alternate days vs continuous • Bio-compatible dialyzer membranes

More Related